Back Back
<i>EGFR</i> ex20ins+ NSCLC

CME

EGFR Exon 20–Altered NSCLC: A Personalized Approach to Improve Patient Outcomes

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit™

Released: November 17, 2021

Expiration: November 16, 2022

CME/CE Information

Activity

Progress
1
Course Completed

References

  1. Riess JW, Gandara DR, Frampton GM, et al. Diverse EGFR exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC. J Thorac Oncol. 2018;13:1560-1568.
  2. Skoulidis F, Heymach JV. Co-occurring genomic alterations in non-small cell lung cancer biology and therapy. Nat Rev Cancer. 2019;19:495-509.
  3. Byeon S, Kim Y, Lim SW, et al. Clinical outcomes of EGFR exon 20 insertion mutations in advanced non-small cell lung cancer in Korea. Cancer Res Treat. 2019;51:623-631.
  4. Yang G, Li J, Xu H, et al. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: molecular heterogeneity and treatment outcome from nationwide real-world study. Lung Cancer. 2020;145:186-194.
  5. Girard N, Bazhenova L, Minchom A, et al. Comparative clinical outcomes for patients with NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Presented at: 22nd World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; January 28-31, 2021. Abstract MA04.07.
  6. Bauml JM, Viteri S, Minchom A, et al. Underdiagnosis of EGFR Exon 20 insertion mutation variants: estimates from NGS-based real-world datasets. Presented at: 22nd World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; January 28-31, 2021. Abstract FP07.12.
  7. Amivantamab-vmjw prescribing information. Horsham, PA: Janssen Biotech, Inc; 2021.
  8. Jatkoe T, Wang S, Odegaard J, et al. Validation of companion diagnostics for the identification of patients with EGFR exon20ins NSCLC for amivantamab therapy. Presented at: 23rd World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; September 8-14, 2021. Abstract P24.14.
  9. Xu C-W, Wang W-X, Wang D, et al. Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study. Transl Lung Cancer Res. 2020;9:1853-1861.
  10. Wu J-Y, Yu C-J, Shih J-Y. Effectiveness of treatments for advanced non-small-cell lung cancer with exon 20 insertion epidermal growth factor receptor mutations. Clin Lung Cancer. 2019;20:e620-e630.
  11. Socinski MA, Nishio M, Jotte RM, et al. IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC. J Thorac Oncol. 2021;16:1909-1924.
  12. Vasconcelos P, Gergis C, Viray H, et al. EGFR-A763_Y764insFQEA is a unique exon 20 insertion mutation that displays sensitivity to approved and in-development lung cancer EGFR tyrosine kinase inhibitors. JTO Clin Res Rep. 2020;1:100051.
  13. Hirose T, Ikegami M, Endo M, et al. Extensive functional evaluation of exon 20 insertion mutations of EGFR. Lung Cancer. 2021;152:135-142.
  14. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: non-small-cell lung cancer. v6.2021. nccn.org. Accessed October 29, 2021.
  15. Osimertinib prescribing information. Wilmington, DE: AstraZeneca; 2019.
  16. van Veggel B, Vilacha Madeira R Santos JF, Hashemi SMS, et al. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer. Lung Cancer. 2020:141:9-13.
  17. Zwierenga F, van Vettel, BA, Hendricks, LE, et al. High-dose osimertinib in patients with advanced stage EGFR exon20 mutation-positive NSCLC: results from a phase 2 multicenter study, POSITION20. Presented at: European Society for Medical Oncology Congress 2021; September 16-21, 2021. Abstract 1214P.
  18. Bazhenova L, Girard N, Michom A, et al. Comparative clinical outcomes between EGFR exon20ins and wildtype NSCLC treated with immune checkpoint inhibitors. Presented at: 23rd World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; September 8-24, 2021. Abstract P08.04.
  19. Socinski MA, Cornelissen R, Garassino MC, et al. ZENITH20, a multinational, multi-cohort phase II study of poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations. Presented at: European Society for Medical Oncology Congress 2020; September 19-21, 2020. Abstract LBA60.
  20. Cornelissen R, Garassino MC, Le X, et al. Updated efficacy, safety and dosing management of poziotinib in previously treated EGFR and HER2 exon 20 NSCLC patients. Presented at: 22nd World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; January 28-31, 2021. Abstract MA11.04.
  21. Le X, Garassino MC, Cornelissen R, et al. CNS activity of poziotinib in NSCLC with exon 20 insertion mutations. Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 9093.
  22. Zhou C, Ramalingam S, Kim TM, et al. Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion–positive metastatic non–small cell lung cancer: A phase 1/2 open-label nonrandomized clinical trial. JAMA Oncol. 2021;Epub ahead of print.
  23. Riely GJ, Neal JW, Camidge DR, et al. Activity and safety of mobocertinib (TAK-788) in previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations from a phase I/II trial. Cancer Discov. 2021;11:1688-1699.
  24. Spira AI, Ramalingam, SS, Neal, JW, et al. Mobocertinib in EGFR exon 20 insertion-positive metastatic NSCLC patients with disease control on prior EGFR TKI therapy. Presented at: 23rd World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; September 8-14, 2021. Abstract OA15.01.
  25. Mobocertinib prescribing information. Lexington, MA: Takeda Pharmaceuticals America, Inc; 2021.
  26. ClinicalTrials.gov. A study of TAK-788 in adults with non-small cell lung cancer. clinicaltrials.gov/ct2/show/NCT02716116. Accessed October 29, 2021.
  27. Jӓnne PA, Ramalingam SS, Kim TM, et al. Mobocertinib in platinum-pretreated EGFR exon 20 insertion+ metastatic NSCLC patients with/without prior anti-PD(L)-1 therapy. Presented at: 23rd World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; September 8-14, 2021. Abstract PF09.01.
  28. Yang J C-H, Wang M, Mitchell P, et al. Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations. J Clin Oncol. Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 9008.
  29. Jӓnne P, Wang, M, Paul, M, et al. Phase 1 studies of DZD9008, an oral, selective EGFR/HER2 inhibitor in advanced NSCLC with EGFR exon20 insertion mutation. Presented at: 23rd World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; September 8-14, 2021. Abstract OA15.02.
  30. Piotrowska Z, Yu HA, Yang J C-H, et al. Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR exon 20 insertion mutations (ins20). Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 9077.
  31. Moores SL, Chiu ML, Bushey BS, et al. A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors. Cancer Res. 2016;76:3942-3953.
  32. Vijayaraghavan S, Lipfert L, Chevalier K, et al. Amivantamab (JNJ-61186372), an Fc enhanced EGFR/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte/macrophage trogocytosis. Mol Cancer Ther. 2020;19:2044-2056.
  33. Yun J, Lee S-H, Kim S-Y, et al. Antitumor activity of amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in diverse models of EGFR exon 20 insertion-driven NSCLC. Cancer Discov. 2020;10:1194-1209.
  34. Park K, Haura EB, Leighl NB, et al. Amivantamab in EGFR exon 20 insertion–mutated non–small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. J Clin Oncol. 2021;Epub ahead of print. 
  35. Haura EB, Cho BC, Lee JS, et al. JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC). Presented at: 2019 American Society of Clinical Oncology Annual Meeting; May 31 - June 4, 2019. Abstract 9009.
  36. Sabari JK, Shu CA, Park K, et al. Amivantamab in post-platinum EGFR exon 20 insertion mutant non-small cell lung cancer. Presented at: 22nd World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; January 28-31, 2021. Abstract OA4.04.
  37. ClinicalTrials.gov. Study of amivantamab, a human bispecific EGFR and cMet antibody, in participants with advanced non-small cell lung cancer (CHRYSALIS). clinicaltrials.gov/ct2/show/NCT02609776. Accessed October 29, 2021.
  38. Nagasaka M, Goto K, Gomez JE, et al. Amivantamab in combination with chemotherapy in patients with advanced non-small cell lung cancer. Presented at: 23rd World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; September 8-14, 2021. Abstract P50.04.
  39. Agrawal T, Artis E, Xie J, et al. PAPILLON: randomized phase 3 study of amivantamab plus chemotherapy vs chemotherapy alone in EGFR exon20ins NSCLC. Presented at: 22nd World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; January 28-31, 2021. Abstract P76.74.
  40. Leighl NB, Shu CA, Minchom A, et al. Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: analysis from the CHRYSALIS study. Presented at: European Society for Medical Oncology Congress 2021; September 16-21, 2021. Abstract 1192M0.
  41. Shu CA, Goto K, Ohe Y, et al. Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): preliminary results from CHRYSALIS-2. Presented at: European Society for Medical Oncology Congress 2021; September 16-21, 2021. Abstract 1193M0.
  42. Spira AI, Krebs MB, Cho BC, et al. Amivantamab in non-small cell lung cancer (NSCLC) with MET exon 14 skipping (METex14) mutation: initial results from CHRYSALIS. Presented at: 22nd World Conference on Lung Cancer of the International Association for the Study of Lung Cancer; January 28-31, 2021. Abstract OA15.03.

BACK | NEXT